Combination drug therapy for advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests two targeted drugs, selumetinib and DS-8201a (trastuzumab deruxtecan), for advanced pancreatic cancer that has spread or cannot be removed. The combination may help people whose tumors have specific markers (KRAS mutation and HER2 positivity).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have pancreatic cancer that has spread or cannot be removed, and it must have a KRAS mutation and be HER2 positive.
- You must have already had at least one line of chemotherapy for advanced disease, or you have chosen not to have standard treatment (for the first part of the study).
- You must be at least 18 years old.
- You must be generally well enough to carry out light activities (ECOG score of 2 or less).
- Your tumor must be measurable on scans, and your blood and organ function must be within required limits.
- You cannot have had certain prior treatments (like MEK/ERK inhibitors or HER2-directed therapy), or have certain lung, eye, heart, or bleeding conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug, telisotuzumab adizutecan, combined with standard chemotherapy (FOLFOX) for people with advanced pancreatic cancer that has spread. The goal is to see if this combination works better than current treatments.
This trial tests a new combination of drugs (ATRA, SDK002, chemotherapy, and an immunotherapy) for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination of two targeted drugs, trastuzumab deruxtecan (Enhertu) and neratinib, for people with solid tumors that have a HER2 gene change. The goal is to see if the combination is safe and works well for cancers that have not responded to at least one prior treatment.
This trial tests a new combination of drugs (TQB2868 injection plus anlotinib capsules) compared to standard chemotherapy for people with pancreatic cancer that has spread to other parts of the body and has not been treated before.
This trial tests a new drug, pegcetacoplan, combined with a standard chemotherapy regimen called modified FOLFIRINOX, for people with pancreatic cancer that has spread to other parts of the body. The goal is to see if the combination helps control the cancer better than chemotherapy alone.
This early-phase trial tests how well targeted medicines (and possibly an immunotherapy drug) work for people with pancreatic cancer that can’t be fully removed with surgery or has spread. It also looks at whether the treatment is safe and can shrink or control tumors by blocking specific cancer pathways.
Hear when a new Advanced Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.